Quick Search (by title or disease)
  

Go to Advanced Search for more options.

Clinical Trials Help

Contact our Cancer Information Line nurse with your questions about open or upcoming clinical trials, second opinions, or patient referrals.
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

Brain cancer Clinical Trials

Protocol Number Title
2003NT036
ALTE03N1 Key Adverse Events After Childhood Cancer (COG study)
2006LS032
MT2005-21 Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors
2008NTCG101
COG ANBL00B1 - Neuroblastoma Biology Studies
2009NTCG026
COG ALTE05N1 Umbrella Long-Term Follow-Up Protocol
2011OC057
MT2011-09C Alkylator-Intense Conditioning Followed By Autologous Transplantation for Patients with High Risk or Relapsed Solid or CNS Tumors
2012OC065
MT2012-11C: Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
2014CG023
COG ADVL1312 - A PHASE 1/2 STUDY OF AZD1775 (MK-1775 , IND# 121422) IN COMBINATION WITH ORAL IRINOTECAN IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY SOLID TUMORS
2015NTCG168
COG APEC14B1 The Project: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome Study Additional Title: EVERYCHILD (APEC14B1) PCR - COG Foundation
2015NTLS018
MT2015-08R: Microbial, Graft and Host Interactions in Hematopoietic Cell Transplantation Reducing sepsis-related mortality in cancer patients through microbiome therapy
2016CG084
COG ALTE1621 - Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial Additional Title: NIH Grant 1R01CA196854: ALTE1621
2016CG156
COG ADVL1513 - A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
2016IS191
A Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX-101) in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors, with or without TRK, ROS1, or ALK Fusions
2016NTLS144
The Development of Data Capture Methodologies in Pediatric Cancer Patients Treated with Targeted Agents and Immunotherapies: Leveraging the Research Infrastructure of a Childhood Cancer Survivor Program
2016NTUC128
The Collection of Blood Samples from Patients with NF1 for Research Purposes
2016NTUC167
A Prospective Study Evaluating the Role of Dietary Intake and Nutritional Status on Neuropathy, Functional Measures of Quality of Life, and Fatigue in Children Receiving Treatment for a Brain Tumor
2017CG036
COG ADVL1515 - A Phase 1 Study of LY2606368 (prexasertib mesylate monohydrate) (IND#132233) a CHK1/2 Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors Added Title: "ADVL1515 - Eli Lilly and Company "
2017CG074
ADVL1622 - Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
2017CG088
ADVL1514 - A Phase 1 Study of ABI-009 (NAB-RAPAMYCIN) in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination With Temozolomide and Irinotecan
2017CG114
COG APEC1621 - NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE) MASTER VERSION CONTROL PROTOCOL
2017CG143
COG ADVL1615 - A Phase I Study of Pevonedistat (MLN-4924, IND#136078), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors
2017IS028
Phase I Trial of Intratumoral Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and human interferon beta (VSV-IFNβ-NIS), in Patients with Refractory Solid Tumors
2017IS061
MT2017-36 :FATE-NK100 as Monotherapy and in Combination with Monoclonal Antibody in Subjects with Advanced Solid Tumors
2017IS062
A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion Combination with Bevacizumab (Bev) versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy
2017IS129
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
2017NTUC078
Building Evidence for Effective Palliative/End of Life Care for Teens with Cancer: FAmily CEntered (FACE) ACP for Teens with Cancer - A multi-site Randomized Control Trial (RCT)
APEC1621H
COG APEC1621H - NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE)-PHASE 2 SUBPROTOCOL OF OLAPARIB IN PATIENTS WITH TUMORS HARBORING DEFECTS IN DNA DAMAGE REPAIR GENES
APEC1621SC
COG APEC1621SC - NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE) SCREENING PROTOCOL
EAY131-Z1C
EAY131-Z1C: MATCH Treatment Subprotocol Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC
EAY131-Z1I
EAY131-Z1I: MATCH Treatment Subprotocol Z1I: Phase II Study of AZD1775 in Patients with Tumors Containing BRCA1 and BRCA2 Mutations
PEDS-2016-25172
Collaborative Perinatal Project Minnesota Cohort Follow-up Study (CPP-MN 2.0)
PEDS-2017-25993
Genetic and early life modifiers of NF1-related outcomes

31 trials displayed